Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida's lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Under the agreement, Catalent will also be granted exclusive manu.

Business Wire • May 13, 2026

Cartherics and Catalent Expand Commercial License Agreement

MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p.

Business Wire • Apr 9, 2026

Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.

Business Wire • Mar 11, 2026

Catalent and S.Biomedics Announce Partnership to Develop and Manufacture TED‑A9

TAMPA, Fla. & SEOUL, South Korea--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease. TED‑A9 represents S.Biomedics' ambition to deliver a new class of regenerative medicine for patients with Parkinson's disease. The program reflects years.

Business Wire • Feb 18, 2026

SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs

TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies.

Business Wire • Jan 12, 2026

Catalent's SMARTag® ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc. presented new advancements in its SMARTag® antibody-drug conjugate (ADC) technology at the 16th World ADC San Diego conference.

Business Wire • Nov 4, 2025

Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focus on “championing the missions that matter.” The new approach reflects Catalent's dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solution.

Business Wire • Oct 28, 2025

Lisata Therapeutics CEO discusses Catalent deal - ICYMI

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of its lead molecule, certepetide, across multiple cancer types and treatment modalities. Proactive: Hello, you're watching Proactive.

Proactive Investors • Oct 11, 2025

Lisata Therapeutics inks global product license deal with Catalent

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) developed using Catalent's SMARTag technology platform.  The clinical-stage pharmaceutical company said Certepetide, a proprietary, internalizing RGD (arginyl-glycyl-aspartic acid), or “iRGD” cyclic peptide, is being tested by Lisata as a cancer therapeutic to be used in combination with other anti-cancer agents to enhance tumor targeting and penetration and improve treatment outcomes.

Proactive Investors • Oct 8, 2025

Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More

Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research

GlobeNewsWire • Jun 6, 2025